The Novo Nordisk Foundation, the philanthropic fund behind the maker of blockbuster drugs Ozempic and Wegovy, will give more ...

Charles R. Goulding and Preeti Sulibhavi discuss how Novo Holdings is channeling the massive success of weight loss drug ...

COPENHAGEN, Denmark, June 4, 2024 /PRNewswire/ -- The Novo Nordisk Foundation has awarded a grant of up to USD 21.1 million to CIMMYT for a groundbreaking initiative to mitigate the environmental ...

Catalent said on Wednesday its stockholders have voted to approve its deal with Novo Holdings, the parent company of Novo ...

Ozempic and Wegovy may be able to significantly reduce the risk of kidney complications, heart issues, and death in patients ...

In 2023, the Novo Nordisk Foundation awarded a record $1.3 billion to projects related to innovation and science. No other foundation in Denmark—including those attached to large companies like ...

The Novo Nordisk Foundation, the majority owner of Novo Nordisk, plans to put more money into regenerative medicines, ...

Novo Holdings is the investment arm of the Novo Nordisk Foundation and has 77% of voting shares in Novo Nordisk, which produces blockbuster obesity drug Wegovy and diabetes treatment Ozempic.

CONTEXT Novo Holdings is the investment arm of the Novo Nordisk Foundation and has 77% of voting shares in Novo Nordisk, which produces blockbuster obesity drug Wegovy and diabetes treatment Ozempic.

the Novo Nordisk Foundation. Sign up here. Reporting by Sriparna Roy in Bengaluru; Editing by Vijay Kishore and Shailesh Kuber Our Standards: The Thomson Reuters Trust Principles.

The scientist — ignored in previous award ceremonies — has won the Princess of Asturias Award for Technical and Scientific ...